Works matching AU Li, Huiping

Results: 309
    1
    2
    3
    4
    5
    6
    7
    8
    9
    10
    11
    12
    13
    14
    15
    16
    17
    18
    19
    20

    Bireociclib plus fulvestrant for HR+/HER2- advanced female breast cancer progressed on or after endocrine therapy: phase 3 BRIGHT-2 study interim analysis.

    Published in:
    Nature Communications, 2025, v. 16, n. 1, p. 1, doi. 10.1038/s41467-025-58647-z
    By:
    • Wang, Jiayu;
    • Zhang, Qingyuan;
    • Li, Huiping;
    • Tong, Zhongsheng;
    • Ouyang, Quchang;
    • Li, Huihui;
    • Teng, Yuee;
    • Wang, Biyun;
    • Sun, Tao;
    • Wang, Jingfen;
    • Li, Wei;
    • Niu, Zhaofeng;
    • Li, Hongsheng;
    • Gong, Chang;
    • Wang, Shu;
    • Wang, Xinshuai;
    • Wu, Xinhong;
    • Liu, Ning;
    • Yu, Guohua;
    • Liu, Fei
    Publication type:
    Article
    21
    22
    23
    24
    25
    26
    27
    28
    29
    30
    31

    A phase 1 trial of fuzuloparib in combination with apatinib for advanced ovarian and triple-negative breast cancer: efficacy, safety, pharmacokinetics and germline BRCA mutation analysis.

    Published in:
    BMC Medicine, 2023, v. 21, n. 1, p. 1, doi. 10.1186/s12916-023-03046-8
    By:
    • Liu, Yaxin;
    • Wang, Wei;
    • Yin, Rutie;
    • Zhang, Youzhong;
    • Zhang, Yu;
    • Zhang, Keqiang;
    • Pan, Hongming;
    • Wang, Ke;
    • Lou, Ge;
    • Li, Guiling;
    • Zhang, Ruyan;
    • Li, Kun;
    • Rao, Jing;
    • Zhang, Ben;
    • Wang, Yuting;
    • Wang, Quanren;
    • Gao, Yunong;
    • Li, Huiping
    Publication type:
    Article
    32
    33
    34
    35
    36
    37
    38
    39
    40
    41
    42
    43
    44
    45
    46
    47
    48
    49
    50